| Date | Title | Description |
| 30.09.2024 | Sequana Medical announces H1 2024 results and provides business update | PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
30 September 2024, 23:55 CEST
Sequana Medical announces H1 2024 results and provides business update
alfapump® - US FDA approval anticipated Q1 2025 and US launch planned for H2 2025;... |
| 21.03.2024 | SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT | - |
| 08.02.2024 | SEQUANA MEDICAL ANNOUNCES EUR 3.0 MILLION CONVERTIBLE FINANCING FROM MAJOR SHAREHOLDERS AND AGREEMENT WITH LENDERS ON DEFERRAL OF DEBT SERVICE PAYMENTS | - |
| 21.06.2023 | Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces additional data on safety, quality of life and survi... |
| 25.04.2023 | SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 15.78 MILLION IN AN EQUITY PLACEMENT | - |
| 09.02.2023 | Sequana Medical announces 2022 Full Year Results and 2023 Outlook | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces its financial results for the year ended 31 Decembe... |
| 08.02.2023 | Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the successful completion of its GLP animal studies... |
| 15.11.2022 | Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces positive top-line results from SAHAR... |
| 08.11.2022 | Sequana Medical to present at Jefferies London Healthcare Conference | /EIN News/ --
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart fail... |
| 25.10.2022 | Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON) | PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
25 October 2022, 07:00 am CET
alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: 100% median per-patient re... |
| 25.10.2022 | Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces positive top-line results from the No... |
| 21.10.2022 | Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting® | Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC:
“An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent Ascites”
Ghent, Belgium – 21 October 2022 ... |
| 21.10.2022 | Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting® | /EIN News/ --
Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC:
“An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent Ascites”
Ghent, Belgium – 21... |
| 08.09.2022 | Sequana Medical announces H1 2022 results and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financia... |
| 08.09.2022 | Sequana Medical announces H1 2022 results and provides business update | PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
8 September 2022, 07:00 CET
alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022DSR® – clinical evidence of d... |
| 01.09.2022 | Sequana Medical Notice of 2022 Half Year Results and Business Update | Ghent, Belgium – 1 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and canc... |
| 25.08.2022 | Alexandra Clyde appointed to Sequana Medical Board of Directors | Seasoned medtech leader with more than 30 years’ healthcare experience
Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of d... |
| 20.07.2022 | Sequana Medical secures EUR 10 million loan facility with Kreos Capital | PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
20 July 2022, 07:00 CET
Company’s cash runway extended into Q3 2023
Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Seq... |
| 19.07.2022 | Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the completion of enrollment in its Phase 2a... |
| 19.07.2022 | Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update | PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
19 July 2022, 07:00 am CEST
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA Ii with first-generation DSR product (“DSR 1.0”) – extending stu... |
| 19.07.2022 | Doug Kohrs appointed to Sequana Medical Board of Directors | Highly experienced US medtech leader brings more than 40 years’ experience
Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of... |
| 05.04.2022 | Sequana Medical announces the completion of alfapump® implantations in POSEIDON, the North American pivotal alfapump study | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure, today announces that it has compl... |
| 10.03.2022 | Sequana Medical announces new Share Capital Amount and New Number of Shares | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that in the context of t... |
| 08.03.2022 | SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 28.4 MILLION IN AN EQUITY PLACEMENT | THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW
PRESS RELEASE
REGULATE... |
| 14.02.2022 | Sequana Medical N : receives certification under MDR, the new European Medical Device Regulation | alfapump® is one of the first novel Class III active implantable medical devices to be certified
Ghent, Belgium - 14 February 2022- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an in... |
| 03.02.2022 | Sequana Medical N : to present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | Ghent, Belgium - 3 February 2022- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites ... |
| 24.01.2022 | Sequana Medical N : ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES | PRESS RELEASE
REGULATED INFORMATION
21 January 2022, 06:00 pm CET
Ghent, Belgium - 21 January 2022 - Sequana Medical NV(Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diur... |
| 17.12.2021 | Sequana Medical N : to attend 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright BIOCONNECT Virtual Conference | CEO Ian Crosbie to participate in a panel discussion on "MedTech and digital tools: What is the Mindset for 2022?"
Ghent, Belgium - 17 December 2021- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "S... |
| 07.12.2021 | Sequana Medical N : announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion | PRESS RELEASE
REGULATED INFORMATION - INSIDE INFORMATION
7 December 2021, 07:00 am CET
Interim data from six patients indicate that alfapump DSR therapy can:
safely, effectively and rapidly eliminate persistent congestion and restore euvole... |
| 06.12.2021 | Sequana Medical Announces the Completion of Patient Enrolment in POSEIDON, the North American Pivotal alfapump Study | Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces the completion of patient enrolment in POSEIDON, the North American pivotal study to sup... |
| 06.12.2021 | Sequana Medical N : announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study | Positive interim analysis reported in July 2021
Reporting of primary endpoint planned for Q4 2022
Ghent, Belgium - 6 December 2021- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an in... |
| 09.11.2021 | Sequana Medical to present at Jefferies London Healthcare Conference | Ghent, Belgium - 9 November 2021- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announ... |
| 03.11.2021 | Sequana Medical receives MDSAP certification and expands its Quality Management System towards North America | Ghent, Belgium - 3 November 2021- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announ... |
| 02.09.2021 | Sequana Medical announces H1 2021 results and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial re... |
| 02.09.2021 | Sequana Medical N : announces H1 2021 results and provides business update | alfapump® – Positive results from second interim analysis of POSEIDON pivotal study; awaiting FDA approval on POSEIDON pivotal study expansion
alfapump® – FDA regulatory submission now expected in mid-2023 due to worldwide supply shortage o... |
| 06.07.2021 | Sequana Medical's results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress | Ghent, BELGIUM – 6 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and... |
| 01.07.2021 | Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results fr... |
| 01.06.2021 | Sequana Medical announces first patient enrolled in SAHARA DESERT | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the SAHARA ... |
| 11.05.2021 | SEQUANA MEDICAL N.V.
Sequana Medical Announces Strong Top-Line Results from RED DESERT alfapump DSR® Study and Expansion of DSR® Development Programme | RED DESERT data of all patients confirm:
alfapump DSR is highly effective at managing fluid and sodium balance in diuretic-resistant heart failure patients without need for loop diuretics restoration of diuretic response and improvement in ... |
| 25.03.2021 | SEQUANA MEDICAL N.V.
Sequana Medical N : ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES | PRESS RELEASE
REGULATED INFORMATION
25 March 2021, 06:00 pm CET
Ghent, Belgium, 25 March 2021 - Sequana Medical NV(Euronext Brussels: SEQUA) (the 'Company' or 'Sequana Medical'), an innovator in the treatment of diuretic-resistant fluid ove... |
| 17.03.2021 | Sequana Medical announces 2020 Full Year Results and 2021 Outlook | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended... |
| 17.03.2021 | SEQUANA MEDICAL N.V.
Sequana Medical Announces 2020 Full Year Results and 2021 Outlook | POSEIDON – positive interim results in Q4 2020; additional interim results expected in
Q2 2021 and primary endpoint in Q2 2022RED DESERT – positive interim results in Q4 2020; top-line data expected in Q2 2021Successful equity placements ex... |
| 19.11.2020 | Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from the first 13 patients in the Roll-In Cohort... |
| 03.09.2020 | Sequana Medical announces H1 2020 results and provides business update | PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
03 September 2020, 07:00 CEST
POSEIDON – Implants in Canada continue; interim results expected H1 2021
RED DESERT – Implants continue; interim results expected Q4 2020
DSR (Direct Sod... |
| 03.09.2020 | SEQUANA MEDICAL N.V.
Sequana Medical announces H1 2020 results and provides business update | POSEIDON – Implants in Canada continue; interim results expected H1 2021
RED DESERT – Implants continue; interim results expected Q4 2020
DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe
Continued growth in Europ... |
| 03.09.2020 | Sequana Medical announces H1 2020 results and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financia... |
| 30.05.2020 | RELAY MEDICAL CORP.
Relay Medical : Announces Closing of Private Placement for Proceeds of Over $600,000 | DGAP-News: Relay Medical Corp. / Key word(s): Miscellaneous
Relay Medical Announces Closing of Private Placement for Proceeds of Over $600,000
29.05.2020 / 23:35
The issuer is solely responsible for the content of this announcement.
Toronto... |
| 19.03.2020 | Sequana Medical announces 2019 Full Year Results and 2020 Outlook | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended 31 December 2019,... |
| 10.01.2020 | Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation | Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failur... |
| 07.01.2020 | Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients | The study aims to: |
| 25.09.2019 | Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period en... |
| 25.09.2019 | Sequana Medical announces first patient enrolled in North American alfapump® pivotal study (POSEIDON) | • Study aims to support the approval of the alfapump in U.S. and Canada
• Results anticipated by mid-2021
• U.S. launch of the alfapump planned for H1 2022 |
| 19.09.2019 | Sequana Medical appoints leading experts as Heart Failure Scientific Advisors | Dr Butler, Dr Costanzo, Dr Tang and Dr Testani to advise on alfapump® DSR development |
| 27.05.2019 | Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure | Ghent, Belgium: 27 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignan... |
| 27.05.2019 | Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure | Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imba... |
| 30.04.2019 | Sequana Medical announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress | Ghent, Belgium: 30 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malign... |
| 04.04.2019 | Sequana Medical announces 2018 Full Year Results and 2019 Outlook | Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, to... |
| 31.01.2019 | Sequana Medical Launches IPO on Euronext Brussels | Sequana Medical NV, a Ghent, Belgium-based commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance ... |
| 15.11.2018 | UK NICE recommends use of Sequana’s alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements | Ghent, Belgium: 15 November 2018 – Sequana Medical NV, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fl... |
| 08.11.2018 | Sequana Medical announces the appointments of industry experts Pierre Chauvineau as Chairman and Wim Ottevaere as Non-Executive Director | Ghent, Belgium: 8 November 2018 – Sequana Medical nv, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other flu... |
| 18.10.2018 | Sequana Medical relocates headquarter to Belgium | |
| 15.10.2018 | Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises € 8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shar... | Ghent, Belgium: 15 October 2018 – Sequana Medical NV, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other flu... |
| 17.09.2018 | Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society | Zurich, Switzerland: 17 September 2018 – Sequana Medical AG, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and ot... |
| 17.09.2018 | Sequana Medical announce positive test results supporting its growth strategy | |
| 17.09.2018 | Sequana Medical announces presentation of pre-clinical proof of concept results of its Direct Sodium Removal (DSR) therapy for the management of volume overload in heart failure at the Annual Scientif... | Zurich, Switzerland: 17 September 2018 – Sequana Medical AG, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and ot... |
| 12.07.2018 | Sequana Medical announces the appointment of Kirsten Van Bockstaele as Chief Financial Officer | Zurich, Switzerland: 12 July 2018 – Sequana Medical AG, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other f... |
| 19.03.2018 | Sequana Medical announces publication of results of multicentre randomized controlled study | Zurich, Switzerland: 19 March 2018 – Sequana Medical AG, a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled study in Quality of Li... |
| 24.10.2017 | Sequana Medical announces results of the MOSAIC trial data presented at 2017 AASLD | Zurich, Switzerland: 24 October 2017 – Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, pre... |
| 04.10.2017 | Sequana Medical announces publication of results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T). | Zurich, Switzerland: 4 October 2017 – Sequana Medical AG, a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of “Treatment of refractory ascites with an automated low-flo... |
| 23.10.2015 | Sequana Medical AG raises CHF 9 million | |
| 23.10.2015 | Daily funding roundup - October 23, 2015 | Sunnova Energy secured $300M; Playful raised $25M; Sequana Medical landed $9.3M
Gurgaon-based foodtech startup, Leaping Caravan, has raised $150,000 in funding from a group of angel investors. The raised funding will be used for business ex... |
| 23.10.2015 | Swiss maker of pump for late stage liver disease complications raises $9.3M | Sequana makes a case for its device as a less painful alternative to the current practice — large volume paracentesis, which can involve frequent hospital visits and a painful procedure to drain the excess fluid. The procedure is used for p... |
| 23.10.2015 | Sequana Medical Raises $9.3M in Series C Extension Round | Sequana Medical AG, a Zurich, Switzerland-based medical device company focused on the development and commercialization of innovative implantable pump systems that manage excess fluid within the body, raised CHF 9m ($9.3m) in Series C exten... |
| 28.04.2014 | Sequana Medical AG raises CHF 23 million in a Series C financing led by LSP | |
| 28.04.2014 | Sequana Medical Raises CHF23M in Series C Financing | Sequana Medical AG, a Zurich, Switzerland-based medical device company with innovative fluid management technologies, has raised CHF23m ($26.2m) in a Series C financing.
The round was led by LSP (Life Science Partners), and co-led by NeoMed... |
| 07.01.2014 | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | The six venture-backed spinouts include:
Baronova, a startup trying for weight loss devices that are both non-surgical and non-pharma. The company closed a $27.3 million Series C round in February 2013, which was led by Boston Scientific (B... |
| 10.07.2013 | Three Swiss start-ups selected for the Healthtech Summit in London | |
| 16.04.2013 | Better quality of life for patients suffering from advanced liver disease | |
| 19.10.2012 | Die Finalisten des Swiss Technology Award 2012 stehen fest | |
| - | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | TheraNova is a San Francisco-based sandbox incubator and capital technology developer for medical devices. With one exception, all the ideas for technology are internally generated, CEO Dr. Daniel Burnett said. That’s led to all its medical... |
| - | Swiss maker of pump for late stage liver disease complications raises $9.3M | Sequana Medical, a Swiss medical device manufacturer, has raised a new round of funding to support the expansion in Europe of its implantable pump to treat complications from liver disease and certain cancers and to accelerate groundwork fo... |
